BRUSSELS, April 14, 2026 (GLOBE NEWSWIRE) -- The Eclipse Foundation today announced the Open VSX Security Researcher Recognition Program, a new initiative designed to strengthen the security of the ...
ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...
First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...
CEO Marianne De Backer highlighted several pipeline milestones, stating "we've made significant progress in our ECLIPSE registrational program for hepatitis delta," with first patients now enrolled in ...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...
- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results